Search

Your search keyword '"Yonesaka, Kimio"' showing total 319 results
Start Over Author "Yonesaka, Kimio"
319 results on '"Yonesaka, Kimio"'

3. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial

Author

Yonesaka, Kimio, Hayashi, Hidetoshi, Nakamura, Atsushi, Sato, Yuki, Azuma, Koichi, Sakata, Shinya, Tachihara, Motoko, Ikeda, Satoshi, Yokoyama, Toshihide, Ito, Kentaro, Yano, Yukihiro, Matsumoto, Hirotaka, Daga, Haruko, Hata, Akito, Sakai, Kazuko, Chiba, Yasutaka, Nishio, Kazuto, Yamamoto, Nobuyuki, and Nakagawa, Kazuhiko

Published
2023
Full Text
View/download PDF

5. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Author

Hayashi, Hidetoshi, Yonesaka, Kimio, Nakamura, Atsushi, Fujimoto, Daichi, Azuma, Koichi, Sakata, Shinya, Tachihara, Motoko, Ikeda, Satoshi, Yokoyama, Toshihide, Hataji, Osamu, Yano, Yukihiro, Hirano, Katsuya, Daga, Haruko, Okada, Hideaki, Chiba, Yasutaka, Sakai, Kazuko, Nishio, Kazuto, Yamamoto, Nobuyuki, and Nakagawa, Kazuhiko

Published
2022
Full Text
View/download PDF

10. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

Author

Haratani, Koji, Yonesaka, Kimio, Takamura, Shiki, Maenishi, Osamu, Kato, Ryoji, Takegawa, Naoki, Kawakami, Hisato, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Tsurutani, Junji, Nishio, Kazuto, Doi, Katsumi, Miyazawa, Masaaki, and Nakagawa, Kazuhiko

Subjects
Durvalumab -- Health aspects -- Analysis, Apoptosis -- Health aspects -- Analysis, Cancer -- Health aspects -- Analysis, Atezolizumab -- Health aspects -- Analysis, Nivolumab -- Health aspects -- Analysis, Chemotherapy -- Health aspects -- Analysis, Avelumab -- Health aspects -- Analysis, Immunotherapy -- Health aspects -- Analysis, Pembrolizumab -- Health aspects -- Analysis, Biological products -- Health aspects -- Analysis, Epidermal growth factors, Biochemistry, Chromosomal proteins, Tumors, Cell death, Antibodies, Health care industry
Abstract

Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefore, rational therapeutic combinations are required to improve its efficacy. In our preclinical study, we evaluated the antitumor effect of U3-1402, a human epidermal growth factor receptor 3-targeting (HER3-targeting) antibody-drug conjugate, and its potential synergism with PD-1 inhibition. Using a syngeneic mouse tumor model that is refractory to anti-PD-1 therapy, we found that treatment with U3-1402 exhibited an obvious antitumor effect via direct lysis of tumor cells. Disruption of tumor cells by U3-1402 enhanced the infiltration of innate and adaptive immune cells. Chemotherapy with exatecan derivative (Dxd, the drug payload of U3-1402) revealed that the enhanced antitumor immunity produced by U3- 1402 was associated with the induction of alarmins, including high-mobility group box-1 (HMGB-1), via tumor-specific cytotoxicity. Notably, U3-1402 significantly sensitized the tumor to PD-1 blockade, as a combination of U3-1402 and the PD-1 inhibitor significantly enhanced antitumor immunity. Further, clinical analyses indicated that tumor-specific HER3 expression was frequently observed in patients with PD-1 inhibitor-resistant solid tumors. Overall, U3-1402 is a promising candidate as a partner of immunotherapy for such patients., Introduction Immune checkpoint inhibitor (ICI) therapy has emerged as a standard of care treatment for many types of cancer. The mainstay of such immunotherapy is the programmed cell death-1 (PD-1)/programmed [...]

Published
2020
Full Text
View/download PDF

11. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)

Author

Izawa, Naoki, Shitara, Kohei, Yonesaka, Kimio, Yamanaka, Takeharu, Yoshino, Takayuki, Sunakawa, Yu, Masuishi, Toshiki, Denda, Tadamichi, Yamazaki, Kentaro, Moriwaki, Toshikazu, Okuda, Hiroyuki, Kondoh, Chihiro, Nishina, Tomohiro, Makiyama, Akitaka, Baba, Hideo, Yamaguchi, Hironori, Nakamura, Masato, Hyodo, Ichinosuke, Muro, Kei, and Nakajima, Takako Eguchi

Published
2020
Full Text
View/download PDF

15. Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, primary, Maenishi, Osamu, primary, Haratani, Koji, primary, Kawakami, Hisato, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Tsuya, Asuka, primary, Goto, Hiroki, primary, Otsuka, Eri, primary, Okida, Hiroaki, primary, Kobayashi, Maki, primary, Yoshimoto, Ryoto, primary, Funabashi, Masanori, primary, Hashimoto, Yuuri, primary, Hirotani, Kenji, primary, Kagari, Takashi, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

16. Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, primary, Maenishi, Osamu, primary, Haratani, Koji, primary, Kawakami, Hisato, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Tsuya, Asuka, primary, Goto, Hiroki, primary, Otsuka, Eri, primary, Okida, Hiroaki, primary, Kobayashi, Maki, primary, Yoshimoto, Ryoto, primary, Funabashi, Masanori, primary, Hashimoto, Yuuri, primary, Hirotani, Kenji, primary, Kagari, Takashi, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

17. Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, primary, Maenishi, Osamu, primary, Haratani, Koji, primary, Kawakami, Hisato, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Tsuya, Asuka, primary, Goto, Hiroki, primary, Otsuka, Eri, primary, Okida, Hiroaki, primary, Kobayashi, Maki, primary, Yoshimoto, Ryoto, primary, Funabashi, Masanori, primary, Hashimoto, Yuuri, primary, Hirotani, Kenji, primary, Kagari, Takashi, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

20. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

Author

Miura, Yuji, Sukawa, Yasutaka, Hironaka, Shuichi, Mori, Misuzu, Nishikawa, Kazuhiro, Tokunaga, Shinya, Okuda, Hiroyuki, Sakamoto, Takeshi, Taku, Keisei, Nishikawa, Kazuo, Moriwaki, Toshikazu, Negoro, Yuji, Kimura, Yutaka, Uchino, Keita, Shinozaki, Katsunori, Shinozaki, Hiroharu, Musha, Nobuyuki, Yoshiyama, Hirotsugu, Tsuda, Takashi, Miyata, Yoshinori, Sugimoto, Naotoshi, Shirakawa, Tsuyoshi, Ito, Miki, Yonesaka, Kimio, Yoshimura, Kenichi, Boku, Narikazu, Nosho, Katsuhiko, Takano, Toshimi, and Hyodo, Ichinosuke

Published
2018
Full Text
View/download PDF

23. A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Author

Sakai, Kazuko, Takeda, Masayuki, Shimizu, Shigeki, Takahama, Takayuki, Yoshida, Takeshi, Watanabe, Satomi, Iwasa, Tsutomu, Yonesaka, Kimio, Suzuki, Shinichiro, Hayashi, Hidetoshi, Kawakami, Hisato, Nonagase, Yoshikane, Tanaka, Kaoru, Tsurutani, Junji, Saigoh, Kazumasa, Ito, Akihiko, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko, and Nishio, Kazuto

Published
2019
Full Text
View/download PDF

24. Figure S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Author

Yonesaka, Kimio, primary, Haratani, Koji, primary, Takamura, Shiki, primary, Sakai, Hitomi, primary, Kato, Ryoji, primary, Takegawa, Naoki, primary, Takahama, Takayuki, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Takeda, Masayuki, primary, Kato, Sigeki, primary, Maenishi, Osamu, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Okabe, Takafumi, primary, Kudo, Keita, primary, Hasegawa, Yoshikazu, primary, Kaneda, Hiroyasu, primary, Yamato, Michiko, primary, Hirotani, Kenji, primary, Miyazawa, Masaaki, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Author

Suzuki, Shinichiro, primary, Yonesaka, Kimio, primary, Teramura, Takeshi, primary, Takehara, Toshiyuki, primary, Kato, Ryoji, primary, Sakai, Hitomi, primary, Haratani, Koji, primary, Tanizaki, Junko, primary, Kawakami, Hisato, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

26. Table S3 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Author

Yonesaka, Kimio, primary, Haratani, Koji, primary, Takamura, Shiki, primary, Sakai, Hitomi, primary, Kato, Ryoji, primary, Takegawa, Naoki, primary, Takahama, Takayuki, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Takeda, Masayuki, primary, Kato, Sigeki, primary, Maenishi, Osamu, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Okabe, Takafumi, primary, Kudo, Keita, primary, Hasegawa, Yoshikazu, primary, Kaneda, Hiroyasu, primary, Yamato, Michiko, primary, Hirotani, Kenji, primary, Miyazawa, Masaaki, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, primary, Maenishi, Osamu, primary, Haratani, Koji, primary, Kawakami, Hisato, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Tsuya, Asuka, primary, Goto, Hiroki, primary, Otsuka, Eri, primary, Okida, Hiroaki, primary, Kobayashi, Maki, primary, Yoshimoto, Ryoto, primary, Funabashi, Masanori, primary, Hashimoto, Yuuri, primary, Hirotani, Kenji, primary, Kagari, Takashi, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, primary, Maenishi, Osamu, primary, Haratani, Koji, primary, Kawakami, Hisato, primary, Tanaka, Kaoru, primary, Hayashi, Hidetoshi, primary, Sakai, Kazuko, primary, Chiba, Yasutaka, primary, Tsuya, Asuka, primary, Goto, Hiroki, primary, Otsuka, Eri, primary, Okida, Hiroaki, primary, Kobayashi, Maki, primary, Yoshimoto, Ryoto, primary, Funabashi, Masanori, primary, Hashimoto, Yuuri, primary, Hirotani, Kenji, primary, Kagari, Takashi, primary, Nishio, Kazuto, primary, and Nakagawa, Kazuhiko, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figures 1 - 10 from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

Author

Cho, Jeonghee, primary, Chen, Liang, primary, Sangji, Naveen, primary, Okabe, Takafumi, primary, Yonesaka, Kimio, primary, Francis, Joshua M., primary, Flavin, Richard J., primary, Johnson, William, primary, Kwon, Jihyun, primary, Yu, Soyoung, primary, Greulich, Heidi, primary, Johnson, Bruce E., primary, Eck, Michael J., primary, Jänne, Pasi A., primary, Wong, Kwok-Kin, primary, and Meyerson, Matthew, primary

Published
2023
Full Text
View/download PDF

35. Data from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

Author

Cho, Jeonghee, primary, Chen, Liang, primary, Sangji, Naveen, primary, Okabe, Takafumi, primary, Yonesaka, Kimio, primary, Francis, Joshua M., primary, Flavin, Richard J., primary, Johnson, William, primary, Kwon, Jihyun, primary, Yu, Soyoung, primary, Greulich, Heidi, primary, Johnson, Bruce E., primary, Eck, Michael J., primary, Jänne, Pasi A., primary, Wong, Kwok-Kin, primary, and Meyerson, Matthew, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Methods from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

Author

Cho, Jeonghee, primary, Chen, Liang, primary, Sangji, Naveen, primary, Okabe, Takafumi, primary, Yonesaka, Kimio, primary, Francis, Joshua M., primary, Flavin, Richard J., primary, Johnson, William, primary, Kwon, Jihyun, primary, Yu, Soyoung, primary, Greulich, Heidi, primary, Johnson, Bruce E., primary, Eck, Michael J., primary, Jänne, Pasi A., primary, Wong, Kwok-Kin, primary, and Meyerson, Matthew, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legend from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

Author

Cho, Jeonghee, primary, Chen, Liang, primary, Sangji, Naveen, primary, Okabe, Takafumi, primary, Yonesaka, Kimio, primary, Francis, Joshua M., primary, Flavin, Richard J., primary, Johnson, William, primary, Kwon, Jihyun, primary, Yu, Soyoung, primary, Greulich, Heidi, primary, Johnson, Bruce E., primary, Eck, Michael J., primary, Jänne, Pasi A., primary, Wong, Kwok-Kin, primary, and Meyerson, Matthew, primary

Published
2023
Full Text
View/download PDF

39. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

Author

Mitani, Seiichiro, primary, Kawakami, Hisato, additional, Shiraishi, Osamu, additional, Kanemura, Hiroaki, additional, Suzuki, Shinichiro, additional, Haratani, Koji, additional, Hayashi, Hidetoshi, additional, Yonesaka, Kimio, additional, Chiba, Yasutaka, additional, Yasuda, Takushi, additional, and Nakagawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

40. Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report

Author

Fujimoto, Kana, primary, Watanabe, Satomi, additional, Yasuda, Yuto, additional, Date, Emi, additional, Kawabata, Yasuhiro, additional, Kanemura, Hiroaki, additional, Takahama, Takayuki, additional, Yonesaka, Kimio, additional, Iizuka, Norishige, additional, Takahashi, Ken‐ichi, additional, Kawakami, Osamu, additional, Ozaki, Tomohiro, additional, and Nakagawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

42. P35-7 Analysis of BRCA1/2 mutations for metastatic castration resistant prostate cancer in clinical practice

Author

Fujita, Kazutoshi, primary, Nakayma, Takahito, additional, Inoguchi, Syunsuke, additional, Fujimoto, Saizo, additional, Hashimoto, Mamoru, additional, Kikuchi, Takashi, additional, Nishimoto, Mitsuhisa, additional, Adomi, Shogo, additional, Banno, Eri, additional, Saito, Yoshitaka, additional, Shimizu, Nobutaka, additional, Mori, Yasunori, additional, Minami, Takafumi, additional, Takahama, Takayuki, additional, Yonesaka, Kimio, additional, Nozawa, Masahiro, additional, Nose, Kazuhiro, additional, Yoshimura, Kazuhiro, additional, and Uemura, Hirotsugu, additional

Published
2022
Full Text
View/download PDF

44. Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, additional, Maenishi, Osamu, additional, Haratani, Koji, additional, Kawakami, Hisato, additional, Tanaka, Kaoru, additional, Hayashi, Hidetoshi, additional, Sakai, Kazuko, additional, Chiba, Yasutaka, additional, Goto, Hiroki, additional, Otsuka, Eri, additional, Okida, Hiroaki, additional, Kobayashi, Maki, additional, Yoshimoto, Ryoto, additional, Funabashi, Masanori, additional, Hashimoto, Yuuri, additional, Hirotani, Kenji, additional, Kagari, Takashi, additional, Nishio, Kazuto, additional, and Nakagawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

45. Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Author

Suzuki, Shinichiro, primary, Yonesaka, Kimio, additional, Teramura, Takeshi, additional, Takehara, Toshiyuki, additional, Kato, Ryoji, additional, Sakai, Hitomi, additional, Haratani, Koji, additional, Tanizaki, Junko, additional, Kawakami, Hisato, additional, Hayashi, Hidetoshi, additional, Sakai, Kazuko, additional, Nishio, Kazuto, additional, and Nakagawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

46. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Author

Takeda, Masayuki, Yamanaka, Takeharu, Seto, Takashi, Hayashi, Hidetoshi, Azuma, Koichi, Okada, Morihito, Sugawara, Shunichi, Daga, Haruko, Hirashima, Tomonori, Yonesaka, Kimio, Urata, Yoshiko, Murakami, Haruyasu, Saito, Haruhiro, Kubo, Akihito, Sawa, Toshiyuki, Miyahara, Eiji, Nogami, Naoyuki, Nakagawa, Kazuhiko, Nakanishi, Yoichi, and Okamoto, Isamu

Published
2016
Full Text
View/download PDF

47. Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report.

Author

Fujimoto, Kana, Watanabe, Satomi, Yasuda, Yuto, Date, Emi, Kawabata, Yasuhiro, Kanemura, Hiroaki, Takahama, Takayuki, Yonesaka, Kimio, Iizuka, Norishige, Takahashi, Ken‐ichi, Kawakami, Osamu, Ozaki, Tomohiro, and Nakagawa, Kazuhiko

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, ADENOCARCINOMA, LUNG cancer, CARBOPLATIN, IMMUNE checkpoint inhibitors, LUNGS, EPIDERMAL growth factor receptors, LUNG tumors, TREATMENT effectiveness, PACLITAXEL, IMMUNOTHERAPY
Abstract

High‐grade fetal lung adenocarcinoma (H‐FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56‐year‐old man with stage IV H‐FLAC who was successfully treated with carboplatin plus nab‐paclitaxel in combination with atezolizumab. In addition, the tumor was found to be positive for amplification of the human epidermal growth factor receptor 2 gene. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Author

Yonesaka, Kimio, primary, Tanizaki, Junko, additional, Maenishi, Osamu, additional, Haratani, Koji, additional, Kawakami, Hisato, additional, Tanaka, Kaoru, additional, Hayashi, Hidetoshi, additional, Sakai, Kazuko, additional, Chiba, Yasutaka, additional, Tsuya, Asuka, additional, Goto, Hiroki, additional, Otsuka, Eri, additional, Okida, Hiroaki, additional, Kobayashi, Maki, additional, Yoshimoto, Ryoto, additional, Funabashi, Masanori, additional, Hashimoto, Yuuri, additional, Hirotani, Kenji, additional, Kagari, Takashi, additional, Nishio, Kazuto, additional, and Nakagawa, Kazuhiko, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results